Human leukocyte antigen DQ2/8 prevalence in non-celiac patients with gastrointestinal diseases

Table 1 General demographic attributes of study population

	Overall	Liver	Upper functional	Upper organic	IBS	IBD
Total number	443	188	73	41	105	36
Gender
Male	44.9%	62.8%	27.4%	34.2%	27.6%	50%
Female	55.1%	37.2%	72.6%	65.8%	72.4%	50%
Age (yr)
Median	56	61	50	57	43	32
Range	72	66	71	66	62	60
Quartiles
14-41	-	4.81%	30.1%	24.4%	45.6%	55.6%
42-56	-	23.5%	28.8%	24.4%	28.2%	19.4%
57-65	-	38.5%	21.9%	12.2%	10.7%	8.3%
66-86	-	33.2%	19.2%	39%	15.5%	16.7%

IBS: Irritable bowel syndrome; IBD: Inflammatory bowel disease.

Table 2 Prevalence of human leukocyte antigen DQ2/8 by age, gender and gastrointestinal disease

	Proportion of positive subjects	Prevalence	P value
Overall	196/443	44.2%	0.02
Gender1
Male	92/199	46.2%
Female	104/244	42.6%	0.45
Age (yr)
14-41	48/108	44.4%
42-56	42/111	37.8%
57-65	53/107	49.5%
66-85	52/114	45.6%	0.37
Disease groups
Liver	86/188	45.7%
Upper functional	39/73	53.4%
Upper organic	19/41	46.3%
IBS	38/105	36.2%
IBD	14/36	38.9%	0.21

¹P > 0.05 for differences between genders in each disease group except for those with upper functional disorders. In these patients significantly more males were positive than females (P = 0.05). IBS: Irritable bowel syndrome; IBD: Inflammatory bowel disease.

Table 3 Magnitude of associations between human leukocyte antigen positivity and specific gastrointestinal disease

Disease group	Odds ratio	95%CI
Overall	1.2	0.96-1.6
Liver	1.3	0.94-1.8
Upper functional	1.8	1.1-2.9
Upper organic	1.3	0.71-2.7
IBS	0.89	0.57-1.4
IBD	0.99	0.49-1.9

IBS: Irritable bowel syndrome; IBD: Inflammatory bowel disease.

Table 4 Positive anti-tTg subject stratified by disease group

Disease group	n	Prevalence
Liver	0/173	0%
Upper functional	1/64	1.54%
Upper organic	0/35	0%
IBS	4/90	4.26%
IBD	0/36	0%

P = 0.04, for any difference in prevalence of anti-tTg positive between disease groupings. IBS: Irritable bowel syndrome; IBD: Inflammatory bowel disease.

Table 5 Prevalence of specific human leukocyte antigen DQ2/8 alleles between gastrointestinal and control populations n (%)

Overall	Gastrointestinal	Controls	Risk
DQ2 and DQ8	2 (0.45)	1 (0.2)	1:45
DQ2, β1*02/*02	17 (3.8)	13 (2.4)	1:63
DQ8, β1*02 positive	8 (1.8)	4 (0.7)	1:39
β2, β1*02/*02	11 (2.5)	2 (0.4)	1:16
DQ2, β1*02/X	85 (19.2)	106 (19.2)	1:100
DQ8, β1*02 negative	32 (7.2)	36 (6.5)	1:90
β2, β1*02/X	41 (9.3)	53 (9.7)	1:104
α5 + other	247 (55.8)	336 (60.9)	1:101
Total	443	551

Omnibus DQ2/8 positive vs DQ2/8 negative χ²; P = 0.16. IBS: Irritable bowel syndrome; IBD: Inflammatory bowel disease.